Dr Martin Zeidler
Room: D43/D43a Firth Court
Brief career history
My lab is interested in identifying and analysing regulators of the JAK/STAT pathway– a signaling cascade frequently misactivated in haematopoietic malignancies. We use both high throughput RNAi screening technologies and developmental genetic assays in Drosophila to determine the mechanisms of action of pathway regulators and their interactions in vivo.
In the news
JAK/STAT signalling in development and disease
My lab studies the regulators and roles of the JAK/STAT signal transduction cascade using a combination of human cell based approaches, Drosophila-based genetic screening and in vivo biology. This work is aimed at generating insights into human inflammatory and haematopoietic disease.
The JAK/STAT pathway transduces the signals provided by multiple cytokines, growth factors and interferons. As a consequence, it plays a central role in development, cellular proliferation, stem cell maintenance, haematopoiesis and immunity. In addition, inappropriate pathway activation is also linked to a wide range of human diseases including cancers, leukaemias, myeloproliferative neoplasms (MPNs) and inflammatory diseases such as rheumatoid arthritis. Conserved throughout evolution, the pathways biological roles have also been largely maintained and as a result, many of the findings made in low complexity model systems such as Drosophila are applicable to humans.
The Zeidler lab has collaborations with a number of high profile groups including that of Tony Green (Cambridge) and Stefan Constantinescu (Brussels). I have also collaborated and co-supervised joint PhD students with the Strutt and Smythe labs (BMS) and the Bellantuono lab (Human Metabolism). In the future, I anticipate working more closely on Drosophila haematopoiesis (with lab of Iwan Evans) and on inflammatory aspects of JAK/STAT signalling humans.
In addition, we are also developing Zebrafish models of human myeloproliferative neoplasms in collaboration with the laboratory of Dr Rob Wilkinson (Cardiovascular Science). Insights gained from this work will also inform analysis using patient material which will be undertaken with Sally Thomas and John Snowden (NHS, Haematology). Finally, ‘drug repurposing’ relating to our discovery of Methotrexate as a potent inhibitor of JAK/STAT pathway signalling will also be pursued.
Undergraduate and postgraduate taught modules
- Chinnaiya K, Lawson MA, Thomas S, Haider M-T, Down J, Chantry AD, Hughes D, Green A, Sayers JR, Snowden JA & Zeidler MP (2017) Low-dose methotrexate in myeloproliferative neoplasm models.. Haematologica, 102, e336-e339. View this article in WRRO
- Thomas S, Fisher KH, Snowden JA, Danson SJ, Brown S & Zeidler MP (2015) Methotrexate Is a JAK/STAT Pathway Inhibitor. PLOS ONE, 10(7). View this article in WRRO
- Wells RE, Barry JD, Warrington SJ, Cuhlmann S, Evans P, Huber W, Strutt D & Zeidler MP (2013) Control of tissue morphology by Fasciclin III-mediated intercellular adhesion.. Development, 140(18), 3858-3868.
- Bausek N & Zeidler MP (2013) Gα73Β is a downstream effector of JAK/STAT signaling and a regulator of Rho1 in Drosophila hematopoiesis. J Cell Sci.
- Müller P, Kuttenkeuler D, Gesellchen V, Zeidler MP & Boutros M (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference.. Nature, 436(7052), 871-875.